The estimated Net Worth of Alejandra Carvajal is at least $1.69 million dollars as of 13 January 2024. Ms Carvajal owns over 11,458 units of Mersana Therapeutics Inc stock worth over $56,258 and over the last 6 years she sold MRSN stock worth over $1,120,295. In addition, she makes $511,294 as SVP et Sec. & Chief Legal Officer at Mersana Therapeutics Inc.
Ms has made over 17 trades of the Mersana Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 11,458 units of MRSN stock worth $20,281 on 13 January 2024.
The largest trade she's ever made was exercising 13,250 units of Mersana Therapeutics Inc stock on 26 April 2023 worth over $23,453. On average, Ms trades about 4,337 units every 69 days since 2018. As of 13 January 2024 she still owns at least 31,784 units of Mersana Therapeutics Inc stock.
You can see the complete history of Ms Carvajal stock trades at the bottom of the page.
Alejandra Veronica Carvajal J.D. is the SVP, Sec. & Chief Legal Officer at Mersana Therapeutics Inc.
As the SVP et Sec. & Chief Legal Officer of Mersana Therapeutics Inc, the total compensation of Ms D at Mersana Therapeutics Inc is $511,294. There are 9 executives at Mersana Therapeutics Inc getting paid more, with Anna Protopapas having the highest compensation of $1,739,800.
Ms D is 47, she's been the SVP et Sec. & Chief Legal Officer of Mersana Therapeutics Inc since . There are 14 older and 4 younger executives at Mersana Therapeutics Inc. The oldest executive at Mersana Therapeutics Inc is Lawrence Alleva, 70, who is the Independent Director.
Alejandra's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Mersana Therapeutics Inc executives and other stock owners filed with the SEC include: